Breast Cancer Coverage from Every Angle

Adam Brufsky, MD, PhD, on the Potential Role of Neratinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer

Posted: Monday, July 29, 2019

Adam Brufsky, MD, PhD, of Magee-Womens Hospital and the Hillman Cancer Center at the University of Pittsburgh Medical Center, discusses the potential role of the combination therapy neratinib plus capecitabine in the later-line treatment of women with HER2-positive metastatic breast cancer, based on the phase III NALA trial results.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.